Overview

A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer

Status:
Terminated
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the duration of T reg suppression in patients with metastatic pancreatic cancer receiving Ontak. The goal is to define the optimal time for future dendritic cell vaccine administration.
Phase:
Phase 2
Details
Lead Sponsor:
Loyola University
Collaborators:
Eisai Inc.
Riveria Country Club Organization
Treatments:
Denileukin diftitox
Interleukin-2